Financial Data and Key Metrics Changes - Reported revenue for Q3 2022 was $15.1 million, a decrease of 6% from $16.1 million in Q3 2021, attributed to macro factors [17] - Gross margin increased from 56.3% in the previous year to 62.4% in Q3 2022 due to a favorable solution and network partner mix [17] - Operating expenses rose to approximately $13.2 million in Q3 2022 from about $9 million in the same period last year, primarily due to team expansion and the acquisition of EvinceMed [19] - GAAP net loss was $3.5 million in Q3 2022 compared to a net income of $0.04 million in Q3 2021; non-GAAP net income was approximately $1.3 million or $0.07 per share [20] - Cash, cash equivalents, and short-term investments totaled $78.8 million as of September 30, 2022, down from $87.4 million as of June 30, 2022, due to share buybacks [21] Business Line Data and Key Metrics Changes - The average revenue for top 20 pharmaceutical manufacturers decreased to $2.2 million at the end of Q3 2022 from $2.5 million in the previous year, influenced by delays in contract renewals [23] - Net revenue retention for Q3 2022 was 96%, a reduction compared to Q2 2022, driven by lower revenue growth [24] Market Data and Key Metrics Changes - The company is experiencing a shift in pharma manufacturers reallocating commercial spend towards omnichannel digital solutions, which is expected to capture a significant share of the market [10][15] - The company anticipates having at least six real-world evidence (RWE) deals running in the first half of 2023, which could contribute to over 20% top-line growth [11] Company Strategy and Development Direction - The company is focused on expanding its RWE solutions, which are seen as a significant growth driver aligned with digital trends in the life sciences industry [10][15] - The management emphasizes the importance of innovative partnerships and omni-channel strategies to enhance client relationships and improve gross margins [31] - The company aims to capture a larger market share as pharma spends shift from traditional methods to digital solutions, positioning itself for strong profitable growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism that macro headwinds will subside in 2023, with improvements in FDA drug approvals and employee turnover rates in the life sciences industry [6] - The company is confident in its ability to grow revenue and expand its partner network without needing additional capital for operating purposes [22] - Management highlighted the importance of maintaining a strong balance sheet and cash flow to support future growth opportunities [22] Other Important Information - The company has initiated a $20 million share repurchase program, having bought back 693,000 shares for $12.2 million at an average price of $17.66 [21] - The company continues to strengthen its channel network, recently renewing its exclusive partnership with NewCrop, enhancing its e-prescribing capabilities [14] Q&A Session Summary Question: Update on channel partners and gross margin - Management noted that channel partnerships are crucial, with a focus on innovative solutions that enhance client relationships and improve gross margins [31] Question: Confidence in Q4 guidance and seasonality - Management expressed a 95% confidence level in achieving the midpoint of the guidance, noting typical seasonal ramp-up in Q4 [33] Question: Details on RWE contracts and contributions to 2023 - Management confirmed that the new RWE contracts are multimillion-dollar deals, contributing positively to gross margins and revenue predictability [40] Question: Competitive landscape and market dynamics - Management indicated that smaller competitors are struggling to deliver on promises, leading to increased client interest in their solutions [42] Question: Retention rates and future expectations - Management believes retention rates are nearing the bottom and expects recovery as new contracts come online [53] Question: Revenue contribution from RWE and contract economics - Management clarified that RWE contracts can range from $0.5 million to $1.5 million in setup fees, transitioning to higher CPM distributions [60] Question: Guidance for Q4 and factors affecting it - Management attributed the wide guidance range to ongoing headwinds and the potential for client buy-ups [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdi ...

Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------|-------|-------|----------------- ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Joy Zhang - SVB Securities Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Marc Wiesenberger - B. Riley Securities Jeff Garro - Piper Sandler Operator Good afternoon, everyone. Thank you for joining OptimizeRx's Second ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...

OptimizeRx Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Ch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdictio ...

OptimizeRx Corporation (NASDAQ:OPRX) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief Operating Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Mark Wiesenberger - B. Riley Securities Max Michaelis - Lake Street Capital Markets Harvey Poppel - Poppel Operator Greetings. Welcome to Optim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...

OptimizeRx Corporation. (NASDAQ:OPRX) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Andrew D’Silva - Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Marc Wiesenberger - B. Riley Securities Eric Martinuzzi - Lake Street Harvey Poppel - Poptech Capital LLP Operator Go ...